Regarding extensive tissue necrosis following high concentration sclerotherapy for varicose veins.
Fisher
D A
DA
D017277:Drug Approval; D006801:Humans; D009336:Necrosis; D000077423:Polidocanol; D011092:Polyethylene Glycols / Q000009:adverse effects; D012597:Sclerosing Solutions / Q000009:adverse effects; D015911:Sclerotherapy / Q000009:adverse effects*; D012981:Sodium Tetradecyl Sulfate / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration; D014648:Varicose Veins / Q000150:complications / Q000628:therapy*
D012597:Sclerosing Solutions; D000077423:Polidocanol; D011092:Polyethylene Glycols; D012981:Sodium Tetradecyl Sulfate